Helius Medical Technologies, Inc. to Present at the 36th Annual ROTH Conference

Rhea-AI Summary

Helius Medical Technologies, Inc. to present at the 36th Annual ROTH Conference, showcasing their innovative neuromodulation approach for balance and gait deficits.

NEWTOWN, Pa., March 07, 2024 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (Nasdaq:HSDT) (“Helius” or the “Company”), a neurotech company focused on delivering a novel therapeutic neuromodulation approach for balance and gait deficits, today announced that Dane Andreeff, President and Chief Executive Officer, and Jeff Mathiesen, Chief Financial Officer, will present at the 36th Annual ROTH Conference, March 17-19, 2024, Laguna Nigel, CA, as follows:

Date:	Monday, March 18, 2024
Time:	1:30pm PT
Webcast:	Click here

Investors and attendees who would like to schedule a 1-on-1 meeting with Helius management are asked to contact their Roth Capital representative.

About Helius Medical Technologies, Inc. 

Helius Medical Technologies is a leading neurotech company in the medical device field focused on neurologic deficits using orally applied technology platform that amplifies the brain’s ability to engage physiologic compensatory mechanisms and promote neuroplasticity, improving the lives of people dealing with neurologic diseases. The Company’s first commercial product is the Portable Neuromodulation Stimulator. For more information visit www.heliusmedical.com.  

About the PoNS Device and PoNS Therapy

The Portable Neuromodulation Stimulator (PoNS) is an innovative, non-implantable, orally applied therapy that delivers neurostimulation through a mouthpiece connected to a controller and it’s used, primarily at home, with physical rehabilitation exercise, to improve balance and gait. The PoNS device, which delivers mild electrical impulses to the tongue, is indicated for use in the United States as a short-term treatment of gait deficit due to mild-to-moderate symptoms from multiple sclerosis (“MS”) and is to be used as an adjunct to a supervised therapeutic exercise program in patients 22 years of age and over by prescription only.

PoNS has shown effectiveness in treating gait or balance and a significant reduction in the risk of falling in stroke patients in Canada, where it received authorization for sale in three indications: (i) for use as a short-term treatment (14 weeks) of gait deficit due to mild and moderate symptoms from stroke and is to be used in conjunction with physical therapy; (ii) for use as a short-term treatment (14 weeks) of chronic balance deficit due to mild-to-moderate traumatic brain injury (“mmTBI”) and is to be used in conjunction with physical therapy; and (iii) for use as a short-term treatment (14 weeks) of gait deficit due to mild and moderate symptoms from MS and is to be used in conjunction with physical therapy. PoNS is also authorized for sale in Australia for short term use by healthcare professionals as an adjunct to a therapeutic exercise program to improve balance and gait. For more information visit www.ponstherapy.com. 

Investor Relations Contact 
Lisa M. Wilson, In-Site Communications, Inc. 
T: 212-452-2793 
E: lwilson@insitecony.com  

 

FAQ

When will Helius Medical Technologies present at the 36th Annual ROTH Conference?

Helius Medical Technologies will present at the 36th Annual ROTH Conference on Monday, March 18, 2024.

What is the focus of Helius Medical Technologies' neuromodulation approach?

Helius Medical Technologies focuses on delivering a novel therapeutic neuromodulation approach for balance and gait deficits.

Who are the key executives presenting at the conference from Helius Medical Technologies?

Dane Andreeff, President and Chief Executive Officer, and Jeff Mathiesen, Chief Financial Officer, will be presenting at the conference.

How can investors schedule a meeting with Helius management at the conference?

Investors and attendees can schedule a 1-on-1 meeting with Helius management by contacting their Roth Capital representative.